Results 21 to 30 of about 53,102 (149)
DENTAL MANAGEMENT AND BLEEDING COMPLICATIONS OF PATIENTS ON LONG-TERM ORAL ANTIPLATELET THERAPY. REVIEW OF EXISTING STUDIES AND GUIDELINES. [PDF]
Journal of IMAB, 2013 Antiplatelet drugs are currently widely used in primary and especially secondary prevention of cardiovascular events. Dental management of patients on antiplatelet therapy is still not clearly defined: the discontinuation of antiplatelet therapy ...
Atanaska Dinkova +2 more
doaj +1 more source
Pharmacogenomics of antiplatelet drugs [PDF]
Hematology, 2014 Abstract Clopidogrel, a platelet P2Y12 inhibitor, is one of the most widely prescribed drugs in cardiovascular medicine because it reduces ischemic and thrombotic complications. It is a prodrug requiring biotransformation into the active metabolite by the hepatic cytochrome 450 system, especially the CYP2C19 enzyme.
Marc S, Sabatine, Jessica L, Mega
openaire +2 more sources
Antiplatelet drug interactions [PDF]
Journal of Internal Medicine, 2010 Abstract. Mackenzie IS, Coughtrie MWH, MacDonald TM, Wei L. (Medicines Monitoring Unit (MEMO); and Centre for Oncology & Molecular Medicine, Division of Medical Sciences, University of Dundee, Ninewells Hospital & Medical School; Dundee, UK). Antiplatelet drug interactions (Review‐Symposium).
Mackenzie, I. S. +3 more
openaire +3 more sources
Research progress of antithrombotic drugs [PDF]
Jichu yixue yu linchuang, 2023 Thrombosis is the main direct cause of acute manifestations of atherosclerotic cardiovascular disease (myocardial infarction, stroke). Globally, the incidence of thromboembolic diseases has increased in recent years, accompanied by an increase in patient
ZHANG Jie, MA Xuzhou, LI Huihui, WANG Miao
doaj +1 more source
Antiplatelet therapy as an element of primary and secondary prevention of ischemic stroke
Медицинский совет, 2016 Antiplatelet medications are essential in the primary and secondary prevention of stroke. All currently available antiplatelet drugs are platelet aggregation inhibitors acting at various points of application, but they differ in their mechanism of action.
E. Y. Solovyova +2 more
doaj +1 more source
NEW ANTIPLATELET DRUGS. PART 2
Рациональная фармакотерапия в кардиологии, 2016 Antiplatelet agents are a necessary component of modern therapy of atherosclerosis. The difficulties of the antiplatelet treatment lie in balance between the necessary therapeutic effect and the risk of excessive action, leads to the bleeding.
A. B. Sumarokov
doaj +1 more source
BMC Geriatrics, 2019 Background Little is known about the effects of continued antiplatelet therapy in patients who receive physician home visits. This study aimed to evaluate the association of survival with the continuation of antiplatelet drugs in patients who received ...
Yasuhiro Osugi +4 more
doaj +1 more source
National Journal of Physiology, Pharmacy and Pharmacology, 2019 Background: Cardiovascular disease is both highly prevalent and expensive to treat. Many novel anticoagulants, fibrinolytics, and antiplatelet agents have been found to be effective in decreasing the morbidity and mortality associated with cardiovascular
Deepak K R, Geetha A
doaj +1 more source
Frontiers in Pharmacology, 2023 Objectives: Long-term use of evidence-based antiplatelet therapy is recommended for management of stable coronary artery disease (SCAD). However, non-adherence to antiplatelet drugs is common in older patients.
Xiao Zou +8 more
doaj +1 more source
ANTITHROMBOTIC THERAPY AT AN ATRIAL FIBRILLATION: OLD PROBLEMS AND NEW SOLUTIONS
Рациональная фармакотерапия в кардиологии, 2016 The problem of antiplatelet drug choice in patients with atrial fibrillation is discussed. Authors give special attention to new alternative drugs for prevention of thrombotic complications apart from old known antiplatelet drugs.
M. Yu. Gilyarov, V. A. Sulimov
doaj +1 more source